SBT6050 + tucatinib + trastuzumab

SBT6050 + tucatinib + trastuzumab is an investigational **triple combination therapy** for the treatment of HER2-positive cancers. - **SBT6050** is a novel antibody-drug conjugate consisting of an anti-HER2 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) agonist, designed to activate myeloid cells within the tumor microenvironment. - **Tucatinib** is a highly selective oral small-molecule tyrosine kinase inhibitor targeting the HER2 receptor, approved for HER2-positive metastatic breast and colorectal cancer, including patients with brain metastases. - **Trastuzumab** is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor, inhibiting HER2-mediated signaling and promoting antibody-dependent cellular cytotoxicity. This combination aims to deliver potent HER2 inhibition via both blockade (trastuzumab, tucatinib) and immune stimulation (SBT6050), addressing resistance mechanisms and promoting tumor killing. Clinical development is primarily in advanced, unresectable, or metastatic HER2-positive solid tumors, with a focus on breast and colorectal cancers.

Other names

SBT6050 + tukysa + herceptin